Eupraxia Pharmaceuticals Files 6-K with Underwriting Agreement
Ticker: EPRX · Form: 6-K · Filed: Sep 23, 2025 · CIK: 1581178
Sentiment: neutral
Topics: filing, underwriting, press-release
TL;DR
Eupraxia Pharma dropped a 6-K with an underwriting deal dated Sept 22 - check the docs!
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 23, 2025, reporting on activities for the month of September 2025. The filing includes an Underwriting Agreement dated September 22, 2025, and two press releases also dated September 22, 2025. Eupraxia Pharmaceuticals Inc. is a foreign private issuer based in Victoria, British Columbia, Canada.
Why It Matters
This filing indicates potential financing or corporate actions by Eupraxia Pharmaceuticals, which could impact its stock price and future operations.
Risk Assessment
Risk Level: medium — Form 6-K filings often contain material updates that can significantly affect a company's stock, but the specific nature of the underwriting agreement and press releases requires further analysis.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- September 22, 2025 (date) — Date of Underwriting Agreement and Press Releases
- September 23, 2025 (date) — Filing Date
- Victoria, British Columbia, Canada (location) — Company Headquarters
FAQ
What is the purpose of the Underwriting Agreement dated September 22, 2025?
The filing does not provide details on the purpose of the Underwriting Agreement, but it is included as Exhibit 99.1.
What information is contained in the press releases dated September 22, 2025?
The filing lists two press releases dated September 22, 2025, as Exhibits 99.2 and 99.3, but their content is not summarized in the provided text.
Is Eupraxia Pharmaceuticals Inc. a US-based company?
No, Eupraxia Pharmaceuticals Inc. is a foreign private issuer located in Victoria, British Columbia, Canada.
What is the SEC file number for Eupraxia Pharmaceuticals Inc.?
The SEC file number for Eupraxia Pharmaceuticals Inc. is 001-41923.
What type of annual report does Eupraxia Pharmaceuticals Inc. file?
Eupraxia Pharmaceuticals Inc. files its annual reports under cover of Form 40-F.
Filing Stats: 168 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2025-09-23 15:51:58
Filing Documents
- d926568d6k.htm (6-K) — 9KB
- d926568dex991.htm (EX-99.1) — 276KB
- d926568dex992.htm (EX-99.2) — 13KB
- d926568dex993.htm (EX-99.3) — 14KB
- g926568g0922092954150.jpg (GRAPHIC) — 7KB
- g926568g0922093105528.jpg (GRAPHIC) — 7KB
- 0001193125-25-213247.txt ( ) — 332KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc.. (Registrant) Date: September 23, 2025 /s/ Alex Rothwell Alex Rothwell Chief Financial Officer